NT
NextPoint Therapeutics, Inc.
SEC filingBiotechnology · Cambridge, MA
Amount raised$33.7Msold at filing
Total offering$48.7M$15M still open
Investors in the raise15count reported to the SEC
FiledJul 30, 2026first sale Jul 22, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Paulina HillDirector
Ivan CheungExecutive Officer, Director
R. Jacob VogelsteinDirector
Jeffrey LaceyExecutive Officer
Brian ShusterDirector
Detlev BiniszkiewiczDirector
Rakhshita DharDirector
Axel HoosDirector
Executive officers, directors and promoters as listed on the Form D.